SSG XXII
09 May 2022
Trial Summary
Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III multicenter study.
Acronym:
SSG XXII
ACTRN/NCT /ethics:
NCT02413736
Scientific title:
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Sponsor / Cooperative group:
Heikki Joensuu
Trial & Patient Characteristics
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years to 100 years |
| Sex | All |
| Tumour Stream | Gastrointestinal stromal tumor |
| Cancer Stage | Early\In Situ |
| Anticipated Start Date | 2015-05-01 |
| Anticipated End Date | 2028-05-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Recruiting |